# antibodies -online.com







# anti-GLA antibody (AA 101-200)

**Images** 



### Overview

Quantity:	100 μL	
Target:	GLA	
Binding Specificity:	AA 101-200	
Reactivity:	Human, Mouse, Rat	
Host:	Rabbit	
Clonality:	Polyclonal	
Conjugate:	This GLA antibody is un-conjugated	
Application:	Western Blotting (WB), ELISA, Flow Cytometry (FACS), Immunohistochemistry (Paraffinembedded Sections) (IHC (p)), Immunofluorescence (Cultured Cells) (IF (cc)), Immunofluorescence (Paraffin-embedded Sections) (IF (p)), Immunohistochemistry (Frozen Sections) (IHC (fro))	

# **Product Details**

Immunogen:	KLH conjugated synthetic peptide derived from human Galactosidase alpha
Isotype:	IgG
Cross-Reactivity:	Human, Mouse, Rat
Predicted Reactivity:	Dog,Cow,Pig,Rabbit
Purification:	Purified by Protein A.

# **Target Details**

Target:	GLA			
---------	-----	--	--	--


# **Target Details**

Target Details			
Alternative Name:	Galactosidase alpha (GLA Products)		
Background:	Synonyms: GALA, Alpha-galactosidase A, Alpha-D-galactosidase A, Alpha-D-galactoside		
	galactohydrolase, Melibiase, GLA		
	Background: Galactosidase alpha is involved in the hydrolysis of terminal, non reducing alpha [		
	galactose residues in alpha D galactosides, including galactose oligosaccharides,		
	galactomannans and galactohydrolase. Defects in GLA are the cause of Fabry's disease (FD).		
	FD is a rare X-linked sphingolipidosis disease where glycolipid accumulates in many tissues.		
	Clinical recognition in males results from characteristic skin lesions (angiokeratomas) over the		
	lower trunk. Patients may show ocular deposits, febrile episodes, and burning pain in the		
	extremities. Death results from renal failure, cardiac or cerebral complications of hypertension		
	or other vascular disease. Heterozygous females may exhibit the disorder in an attenuated		
	form, they are more likely to show corneal opacities.		
Gene ID:	2717		
UniProt:	P06280		
Pathways:	SARS-CoV-2 Protein Interactome		
Application Dataila			
Application Details			
Application Notes:	WB 1:300-5000		
	ELISA 1:500-1000		
	FCM 1:20-100		
	IHC-P 1:200-400		
	IHC-F 1:100-500		
	IF(IHC-P) 1:50-200		
	IF(IHC-F) 1:50-200		
	IF(ICC) 1:50-200		
Restrictions:	For Research Use only		
Handling			
Format:	Liquid		
Concentration:	1 μg/μL		
Buffer:	0.01M TBS( pH 7.4) with 1 % BSA, 0.02 % Proclin300 and 50 % Glycerol.		
Preservative:	ProClin		

# Handling


Precaution of Use:	This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be	
	handled by trained staff only.	
Storage:	4 °C,-20 °C	
Storage Comment:	Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles.	
Expiry Date:	12 months	

## **Images**



# **Immunohistochemistry**

**Image 1.** Formalin-fixed and paraffin embedded human rectal carcinoma labeled with Anti-Galactosidase alpha Polyclonal Antibody, Unconjugated (ABIN872875) at 1:200 followed by conjugation to the secondary antibody and DAB staining.



# SDS-PAGE

**Image 2.** Lane 1: mouse liver lysates Lane 2: human colon carcinoma lysates probed with Anti Galactosidase alpha Polyclonal Antibody, Unconjugated (ABIN872875) at 1:200 in 4 °C. Followed by conjugation to secondary antibody at 1:3000 90min in 37 °C. Predicted band 44kD. Observed band size: 44kD.